Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: A systematic review and meta-analysis

Drug Safety

Volumn 31, Issue 7, 2008, Pages 597-607

  Ormerod, Sara ^a   McDowell, Sarah E ^b   Coleman, Jamie J ^c   Ferner, Robin E ^b,c  

^a QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antidepressants, adverse reactions; Antipsychotics, adverse reactions; Ethnic groups; Meta analysis

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DULOXETINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ANXIETY; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG WITHDRAWAL; DYSTONIA; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; META ANALYSIS; METABOLIC SYNDROME X; MOTIVATION; NEUTROPENIA; PARKINSON RIGIDITY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASAL GANGLIA DISEASES; DYSKINESIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERGLYCEMIA; WEIGHT GAIN;

EID: 45549107737     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831070-00005     Document Type: Review

References (88)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329 (7456): 15-9
2. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327 (7425): 1222-5
3. Morley KI, Hall WD. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. J Mol Med 2004; 82 (1): 21-30
4. Jaquenoud SE, van der Velden JW, Rentsch K, et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29 (9): 735-68
5. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332 (7551): 1177-81
6. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
7. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43 (9): 943-67
8. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet 2004; 36 (11 Suppl.): 34-S42
9. Jorde LB, Wooding SP. Genetic variation, classification and 'race'. Nat Genet 2004; 36 (11 Suppl.): 28-S33
10. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005; 6 (3): 241-6
11. Schwartz RS. Racial profiling in medical research. N Engl J Med 2001; 344 (18): 1392-3
12. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet 2001; 29 (3): 265-9
13. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med 2003; 348 (12): 1166-70
14. Risch N, Burchard E, Ziv E, et al. Categorization of humans in biomedical research: genes, race and disease. Genome Biol 2002; 3 (7): 1-12
15. McKenzie K, Samele C, Van Horn E, et al. Comparison of the outcome and treatment of psychosis in people of Caribbean origin living in the UK and British Whites: report from the UK700 trial. Br J Psychiatry 2001; 178: 160-5
16. Morgan C, Mallett R, Hutchinson G, et al. Pathways to care and ethnicity: 1, sample characteristics and compulsory admission -report from the AESOP study. Br J Psychiatry 2005; 186: 281-9
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33 (1): 159-74
18. British National Formulary. No. 50, 50th edition. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2005
19. Higgins J, Green S. Assessment of study quality. Cochrane handbook for systematic reviews of interventions 4.2.5. Chichester: The Cochrane Collaboration, 2005
20. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 2004; 58 (6): 441-5
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-60
22. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315 (7121): 1533-7
23. Review Manager (RevMan). Oxford: The Cochrane Collaboration, 2002
24. Morgenstern H, Glazer WM, Gibowski LD, et al. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. J Chronic Dis 1987; 40 (4): 319-27
25. Sramek J, Roy S, Ahrens T, et al. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Community Psychiatry 1991; 42 (6): 590-2
26. Richardson MA, Reilly MA, Read LL, et al. Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women. Psychopharmacology (Berl) 1999; 143 (4): 347-57
27. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50 (9): 723-33
28. Van Os J, Fahy T, Jones P, et al. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997; 96 (3): 206-16
29. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52 (9): 756-65
30. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53 (4): 313-9
31. Van Os J, Walsh E, Van Horn E, et al. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatr Scand 2000; 101 (4): 300-6
32. Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64 (9): 1075-80
33. Chong SA, Mahendran R, Machin D, et al. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol 2002; 22 (1): 26-30
34. Bhatia T, Sabeeha MR, Shriharsh V, et al. Clinical and familial correlates of tardive dyskinesia in India and Israel. J Postgrad Med 2004; 50 (3): 167-72
35. Jann MW, Chang WH, Davis CM, et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res 1989; 30 (1): 45-52
36. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138 (9): 1243-4
37. Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140 (4): 490-1
38. Sramek JJ, Sayles MA, Simpson GM. Neuroleptic dosage for Asians: a failure to replicate. Am J Psychiatry 1986; 143 (4): 535-6
39. Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146 (10): 1307-11
40. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160 (2): 290-6
41. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005; 66 (11): 1463-7
42. Sernyak MJ, Gulanski B, Leslie DL, et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003; 64 (5): 605-8
43. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66 (9): 1116-21
44. Barner JC, Worchel J, Yang M. Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy 2004; 24 (11): 1529-38
45. Lamberti JS, Costea GO, Olson D, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry 2005; 66 (7): 900-6
46. Sumiyoshi T, Roy A, Anil AE, et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004; 24 (3): 345-8
47. Lamberti JS, Crilly JF, Maharaj K, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (5): 702-6
48. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67 (4): 575-83
49. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-43
50. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62 (4): 231-8
51. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005; 66 (11): 1468-76
52. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-80
53. Meged S, Stein D, Sitrota P, et al. Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in Jewish Israeli schizophrenic patients. Int Clin Psychopharmacol 1999; 14 (5): 305-12
54. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47 (10): 945-8
55. Fleck DE, Keck Jr PE, Corey KB, et al. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry 2005; 66 (5): 646-52
56. Ciliberto N, Bossie CA, Urioste R, et al. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2005; 20 (4): 207-12
57. Raskin A, Crook TH. Antidepressants in black and white inpatients: differential response to a controlled trial of chlorpromazine and imipramine. Arch Gen Psychiatry 1975; 32 (5): 643-9
58. Matsuda KT, Cho MC, Lin KM, et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996; 32 (2): 253-7
59. Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20 (3): 163-8
60. Moeller FG, Chen YW, Steinberg JL, et al. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995; 7 (4): 167-73
61. Strickland TL, Lin KM, Fu P, et al. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol Psychiatry 1995; 37 (5): 325-30
62. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother 1982; 36 (4): 505-12
63. Sleath B, Rubin RH, Wurst K. The influence of Hispanic ethnicity on patients' expression of complaints about and problems with adherence to antidepressant therapy. Clin Ther 2003; 25 (6): 1739-49
64. Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004; 45 (3): 210-6
65. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998; 49 (2): 239-40
66. Alonso M, Val E, Rapaport MH. An open-label study of SSRI treatment in depressed hispanic and non-Hispanic women [letter]. J Clin Psychiatry 1997; 58 (1): 31
67. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J 2005; 41 (5): 521-37
68. Ayalon L, Arean PA, Alvidrez J. Adherence to antidepressant medications in black and Latino elderly patients. Am J Geriatr Psychiatry 2005; 13 (7): 572-80
69. Ng CH, Norman TR, Naing KO, et al. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 2006; 21 (2): 87-92
70. Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers: preliminary report on a pilot study. Postgrad Med J 1977; 53 Suppl. 4: 79-86
71. Livingston RL, Zucker DK, Isenberg K, et al. Tricyclic antidepressants and delirium. J Clin Psychiatry 1983; 44 (5): 173-6
72. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63 (4): 357-66
73. Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006; 98 (3): 437-47
74. Roy-Byrne PP, Perera P, Pitts CD, et al. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis. J Clin Psychiatry 2005; 66 (10): 1228-33
75. Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians: relation to body lipid stores. Eur J Clin Pharmacol 1987; 32 (2): 211-5
76. Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8 (3): 195-201
77. Chang WH, Chen TY, Lee CF, et al. Low plasma reduced haloperidol/ haloperidol ratios in Chinese patients. Biol Psychiatry 1987; 22 (11): 1406-8
78. Nikelly AG. Does DSM-III-R diagnose depression in non-Western patients? Int J Soc Psychiatry 1988; 34 (4): 316-20
79. Mumford DB. Detection of psychiatric disorders among Asian patients presenting with somatic symptoms. Br J Hosp Med 1992; 47 (3): 202-4
80. Kirmayer LJ, Young A. Culture and somatization: clinical, epidemiological, and ethnographic perspectives. Psychosom Med 1998; 60 (4): 420-30
81. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341 (18): 1329-35
82. Ruiz P, Varner RV, Small DR, et al. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 1999; 70 (2): 163-72
83. Opolka JL, Rascati KL, Brown CM, et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv 2004; 55 (2): 151-6
84. National Center for Chronic Disease Prevention and Health Promotion. Age-adjusted prevalence of diagnosed diabetes per 100 population, by race/ethnicity and sex, United States, 1980-2005 [online]. Available from URL: http://www.cdc.gov/diabetes/statistics/prev/national/tableraceeth-sex.htm [Accessed 2006 Apr 11]
85. The Information Centre. Health survey for England 2004: health of ethnic minorities. Leeds: The Information Centre, 2006
86. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care 2006; 29 (7): 1585-90
87. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication [online]. Available from URL: http://www.icmje.org/ #prepare [Accessed 2006 Apr 11]
88. Derry S, Kong LY, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001; 1: 7